JP2001515708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001515708A5 JP2001515708A5 JP2000510463A JP2000510463A JP2001515708A5 JP 2001515708 A5 JP2001515708 A5 JP 2001515708A5 JP 2000510463 A JP2000510463 A JP 2000510463A JP 2000510463 A JP2000510463 A JP 2000510463A JP 2001515708 A5 JP2001515708 A5 JP 2001515708A5
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- antibody
- humanized
- sasnryt
- ngfwi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/925,339 US6440418B1 (en) | 1995-11-07 | 1997-09-08 | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US08/925,339 | 1997-09-08 | ||
| PCT/US1998/018163 WO1999012566A1 (en) | 1997-09-08 | 1998-09-08 | HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001515708A JP2001515708A (ja) | 2001-09-25 |
| JP2001515708A5 true JP2001515708A5 (cg-RX-API-DMAC10.html) | 2006-07-06 |
Family
ID=25451580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000510463A Abandoned JP2001515708A (ja) | 1997-09-08 | 1998-09-08 | ヒトgp39に対するヒト化抗体、当該抗体を含む組成物およびその治療的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6440418B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1011725A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2001515708A (cg-RX-API-DMAC10.html) |
| KR (1) | KR100574591B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN1278736A (cg-RX-API-DMAC10.html) |
| AU (1) | AU740981B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2302752A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL134888A0 (cg-RX-API-DMAC10.html) |
| NO (1) | NO20001104L (cg-RX-API-DMAC10.html) |
| RU (1) | RU2207878C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1999012566A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| CN1572325A (zh) * | 1997-01-10 | 2005-02-02 | 拜奥根Idec马萨诸塞公司 | 用抗cd40l化合物治疗狼疮性肾炎 |
| CA2223225A1 (en) * | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
| US7163686B1 (en) * | 1999-05-15 | 2007-01-16 | The Regents Of The University Of California | Protein A based binding domains with desirable activities |
| EP1101495A4 (en) * | 1999-06-01 | 2003-05-07 | Eisai Co Ltd | PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| EP1839674A1 (en) * | 1999-10-04 | 2007-10-03 | Novartis Vaccines and Diagnostics, Inc. | CD40 antagonist for treating psoriasis |
| DE60035057T2 (de) * | 1999-10-04 | 2008-01-31 | Novartis Vaccines and Diagnostics, Inc., Emeryville | CD40 Antagonist zur Behandlung von Psoriasis |
| EP1223981B1 (en) * | 1999-10-22 | 2008-01-16 | Biogen Idec MA Inc. | Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| WO2001079555A2 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| EP1284747A2 (en) | 2000-05-12 | 2003-02-26 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
| AU7522401A (en) * | 2000-06-06 | 2001-12-17 | Idec Pharma Corp | Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2003086463A1 (en) * | 2002-04-03 | 2003-10-23 | Keio University | Remedies for pemphigus containing cd40l antagonist as the active ingredient |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| WO2004074432A2 (en) * | 2003-01-31 | 2004-09-02 | Celldex Therapeutics, Inc. | Antibody vaccine conjugates and uses therefor |
| RU2240134C1 (ru) * | 2003-02-17 | 2004-11-20 | Козлов Владимир Александрович | Способ лечения больных сахарным диабетом |
| US20050079234A1 (en) * | 2003-08-27 | 2005-04-14 | Chiang Yang Chi | Compositions comprising herbs and method for immunomodulation |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| AU2006272555B2 (en) | 2005-07-25 | 2012-03-08 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| US8236318B2 (en) | 2007-11-07 | 2012-08-07 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| WO2010003193A1 (en) * | 2008-07-11 | 2010-01-14 | Phylogica Limited | Peptide inhibitors of cd40l signaling and uses therefor |
| BRPI1009455A2 (pt) | 2009-03-10 | 2016-03-01 | Baylor Res Inst | anticorpos anti-c40 e usos dos mesmos |
| BRPI1009454A2 (pt) | 2009-03-10 | 2019-09-24 | Baylor Res Institute | vacinas contra o câncer direcionadas a células apresentadoras de antígenos |
| US20130028897A1 (en) * | 2009-04-27 | 2013-01-31 | Ali Naji | Methods for reducing the level of alloantibodies in a subject |
| RU2439712C1 (ru) * | 2010-07-21 | 2012-01-10 | Сергей Валентинович Логвинов | Способ моделирования аутоиммунного оофорита |
| CN107881196A (zh) * | 2011-12-22 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途 |
| WO2014153056A2 (en) | 2013-03-14 | 2014-09-25 | Parkash Gill | Cancer treatment using antibodies that bing cell surface grp78 |
| WO2015106281A1 (en) | 2014-01-13 | 2015-07-16 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| SG10201913431QA (en) | 2015-07-14 | 2020-03-30 | Immunext Inc | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
| MY188405A (en) | 2015-08-05 | 2021-12-08 | Janssen Biotech Inc | Anti-cd154 antibodies and methods of using them |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| US20230151102A1 (en) | 2020-01-13 | 2023-05-18 | Aptevo Research And Development Llc | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
| CN115279406A (zh) | 2020-01-13 | 2022-11-01 | 阿帕特夫研究和发展有限公司 | 蛋白质治疗剂的调配物 |
| US20240262920A1 (en) | 2021-05-21 | 2024-08-08 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5092585A (en) | 1987-06-11 | 1992-03-03 | Jones Arthur A | Apparatus for testing and/or exercising the cervical muscles of the human body |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| DK0897983T3 (da) | 1991-10-25 | 2003-08-11 | Immunex Corp | Antistoffer mod CD40-L |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| WO1994004570A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| US5540926A (en) | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| JP2840131B2 (ja) | 1993-09-02 | 1998-12-24 | トラスティーズ・オブ・ダートマス・カレッジ | 液性免疫の持続性抑制方法 |
| CN1127351C (zh) * | 1993-09-02 | 2003-11-12 | 达特茅斯学院理事 | 诱导抗原特异性t细胞耐受的方法 |
| US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| GB9507719D0 (en) * | 1995-04-13 | 1995-05-31 | Boc Group Plc | Machining of materials |
| US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| WO1998008541A1 (en) | 1996-08-30 | 1998-03-05 | Genzyme Corporation | Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies |
-
1997
- 1997-09-08 US US08/925,339 patent/US6440418B1/en not_active Expired - Fee Related
-
1998
- 1998-09-08 AU AU95652/98A patent/AU740981B2/en not_active Ceased
- 1998-09-08 CA CA002302752A patent/CA2302752A1/en not_active Abandoned
- 1998-09-08 CN CN98810897A patent/CN1278736A/zh active Pending
- 1998-09-08 EP EP98949305A patent/EP1011725A4/en not_active Withdrawn
- 1998-09-08 WO PCT/US1998/018163 patent/WO1999012566A1/en not_active Ceased
- 1998-09-08 KR KR1020007002445A patent/KR100574591B1/ko not_active Expired - Fee Related
- 1998-09-08 RU RU2000109255/14A patent/RU2207878C2/ru not_active IP Right Cessation
- 1998-09-08 IL IL13488898A patent/IL134888A0/xx unknown
- 1998-09-08 JP JP2000510463A patent/JP2001515708A/ja not_active Abandoned
-
2000
- 2000-03-03 NO NO20001104A patent/NO20001104L/no unknown
-
2002
- 2002-06-17 US US10/171,681 patent/US7122187B2/en not_active Expired - Fee Related
-
2006
- 2006-03-09 US US11/370,898 patent/US20060153837A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2207878C2 (ru) | "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование | |
| ES2384168T3 (es) | Procedimientos de tratamiento usando anticuerpos CTLA-4 | |
| EP2447281B1 (en) | Novel anti-PLGF antibody | |
| JP2022031638A (ja) | 放射線療法と併用されるpd-1およびpd-l1に対する拮抗薬を用いたがんの治療法 | |
| CN1202864C (zh) | Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途 | |
| UA125382C2 (uk) | Антитіла проти людського vista та їх застосування | |
| WO1994008619A1 (en) | Treatment of autoimmune and inflammatory disorders | |
| RU2000109255A (ru) | "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование | |
| RU2009149294A (ru) | Антиген-связывающие белки, нацеленные на orf0657n s.aureus | |
| JP2026050362A (ja) | Car-t細胞のインサイチュ動員、リプログラミングおよび放出 | |
| MXPA06008746A (es) | Metodos y composiciones para tratamiento de tumores y enfermedad metastatica. | |
| CN104105505A (zh) | 用于治疗类风湿性关节炎的组合物及其使用方法 | |
| CN114729031A (zh) | 抗溶瘤病毒抗原抗体及其使用方法 | |
| JP2020510039A5 (cg-RX-API-DMAC10.html) | ||
| US20220259313A1 (en) | Administration of a pd-1 inhibitor for for treating skin cancer | |
| JP2016172759A (ja) | 抗cd3免疫分子療法により肝炎を治療する方法および組成物 | |
| JP2021534195A5 (cg-RX-API-DMAC10.html) | ||
| CN113038939A (zh) | 损害内施用pd-1抑制剂用于治疗皮肤癌 | |
| CN112996909A (zh) | 表达pd-1结合蛋白的溶瘤病毒及其应用 | |
| US20060153805A1 (en) | Viral vectors and the use of the same for gene therapy | |
| JP6890340B6 (ja) | グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 | |
| CN119677533A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| CN118871127A (zh) | 用于治疗头颈癌的三重组合药物给药疗法 | |
| ES2326978T3 (es) | Procedimiento de tratamiento del carcinoma hepatocelular. | |
| JP2003089656A (ja) | 移植による免疫反応抑制剤 |